Claim of CRISPR’d baby girls stuns genome editing summit
By Sharon Begley,
STAT
| 11. 26. 2018
HONG KONG — A Chinese scientist’s claim that he used the genome editing technology CRISPR-Cas9 to alter the DNA of human embryos, resulting in the birth a few weeks ago of twin girls, stunned organizers of the Second International Summit on Human Genome Editing, leaving them scrambling to evaluate the claim two days before the scientist is scheduled to speak at the meeting.
“I don’t know the details” of the claim by He Jiankui, said David Baltimore of the California Institute of Technology, chairman of the organizing committee of the summit, which begins on Tuesday in Hong Kong. “We don’t know what will be said” when He speaks at a session on human embryo editing.
The summit’s organizing committee issued a statement Monday saying they had only just learned of He’s research in Shenzhen, China. “Whether the clinical protocols that resulted in the births in China conformed with the guidance” of leading scientific bodies for conducting clinical trials of heritable genome editing “remains to be determined,” the statement said. “We hope that the dialogue at our summit further advances the...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...